GraniteShares 2x Long NVDA Daily ETF vs Zoetis Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $35.46, while Zoetis Inc trades at $73.51 (market cap $30.40B). The key difference: Zoetis Inc pays a 2.88% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| NVDL | ZTS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $150.61 |
52-Week Low | $21.76 | $71.91 |
Market Cap | — | $30.40B |
Enterprise Value | — | $37.96B |
Dividend Yield | — | 2.88% |
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.18, down 4.01% amid recent volatility. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF recently underwent two 1:3 stock splits in late June 2026, reflecting NVIDIA's continued market leadership in AI semiconductors.
The outlook remains positive given NVIDIA's dominant AI position and earnings beats, though leveraged ETF structure introduces volatility decay risks. Key opportunities include exposure to NVIDIA's growth trajectory, while risks center on market sentiment shifts and the ETF's daily reset mechanism affecting long-term returns.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Trailing returns across standard periods
Latest headlines on both assets
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →